Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Quisinostat
INQ
In stock
SYN-3029-M0011 mgCHF 128.00
SYN-3029-M0055 mgCHF 255.00
SYN-3029-M01010 mgCHF 454.00
SYN-3029-M05050 mgCHF 1'206.00
SYN-3029-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | JNJ-26481585 |
| Product Type | Chemical |
| Properties | |
| Formula | C21H26N6O2 |
| MW | 394.5 |
| CAS | 875320-29-9 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data | Target: HDAC1, 2, 4, 10 and HDAC11 | Kinase Group: N/A | Substrate: N/A |
| InChi Key | PAWIYAYFNXQGAP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Quisinostat (JNJ-26481585) is a novel second-generation panHDAC inhibitor of HDAC1, 2, 4, 10 and 11. Its highest potency is against HDAC1 with an IC50 of 0.11nM. It has only modest potency against HDACs 2, 4, 10, and 11 (IC50 ranging from 0.33nM to 0.64nM). It has low activity against HDACs 3, 5, 8, and 9 and its lowest potency is against HDACs 6 and 7.
Product References
- JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity: J. Arts, et al.; Clin. Cancer Res. 15, 6841 (2009)
- Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585: T. Stuehmer, et al.; Br. J. Haematol. 149, 529 (2010)
Related Products
